Condition: Advanced/Metastatic Solid Tumors · Sponsor: DualityBio Inc.
This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes one randomized dose expansion cohort and two single-arm dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.
This description comes directly from the study's public registry record.
Junhua Gao · 01067228087 · junhua.gao@dualitybiologics.com
Zhaochuan Wang · zhaochuan.wang@dualitybiologics.com
Always discuss trial participation with your own doctor first.
| USA04-0 | Los Angeles, California, United States | Recruiting |
| USA05-0 | Ann Arbor, Michigan, United States | Recruiting |
| Site USA06-0 | Pittsburgh, Pennsylvania, United States | Recruiting |
| USA02-0 | Houston, Texas, United States | Recruiting |
| USA03-0 | San Antonio, Texas, United States | Recruiting |
| USA01-0 | Fairfax, Virginia, United States | Recruiting |
| AUS03-0 | Liverpool, New South Wales, Australia | Recruiting |
| AUS01-0 | Randwick, New South Wales, Australia | Recruiting |
| AUS04-0 | Westmead, New South Wales, Australia | Recruiting |
| AUS02-0 | Nedlands, Western Australia, Australia | Recruiting |
| Chn01-1/Chn01-2 | Guangzhou, Guangdong, China | Recruiting |
| CHN05-0 | Harbin, Heilongjiang, China | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07141706